This Phase I, open-label, randomized, 2-period crossover study was designed to determine the relative bioavailability of ipatasertib administered as capsule and tablet formulations to healthy adult volunteers. Participants will be randomized to one of two treatment sequences to receive a single oral administration of ipatasertib in tablet or capsule formulation followed, after a washout period, by a single oral administration of ipatasertib in the second formulation. Pharmacokinetics will be assessed, and standard physical and clinical evaluations will be performed throughout the study. Time on study is expected to be 2 weeks.

Inclusion Criteria:

• Healthy male and female volunteers aged 18 to 55 years, inclusive
• Body mass index (BMI) from 18.5-29.9 kg/m2, inclusive

Exclusion Criteria:

• Clinically significant findings from medical history or screening evaluations